- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Andrew Vickers addresses concerns about underdiagnosing low-volume Grade Group 2 prostate cancer when considering reclassification of Grade Group 1. He argues that many objections to redesignation are speculative and fail to consider the current problems of overdiagnosis, overtreatment, and patie...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts debate the complexities of prostate cancer classification and the potential reclassification of Grade Group 1 tumors. They explore the importance of cribriform patterns in Pattern 4 cancers and the consistency of pathological identification. The conversation touches on historical changes...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, CJ Stimpson discusses the potential impact of changing nomenclature on alternative payment models (APMs) for prostate cancer. He asserts that such changes would not cause significant problems in developing or executing APMs, as these models are rare for prostate cancer and must already adapt to f...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Derya Tilki challenges the notion that Europe doesn't have issues with active surveillance uptake for prostate cancer, highlighting the heterogeneity across European countries. Dr. Tilki specifically mentions Germany, where only about 30% of eligible patients opt for active surveillance, partly d...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Mohamed Jalloh discusses two significant studies on prostate cancer in Africa. The first, a 2013 evaluation, examines pathology outcomes across six African countries, revealing varying proportions of Gleason 6 cases. The second, a more recent prospective study in West and Southern Africa, analyze...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts debate the evolving landscape of prostate cancer diagnosis and management. They examine the limitations of traditional biopsy methods and the potential of MRI in improving diagnostic accuracy. The conversation highlights the shift towards imaging-based diagnoses in countries like Australi...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Quoc-Dien Trinh discusses the complexities surrounding active surveillance for prostate cancer in racial and ethnic minorities, particularly Black men. He reviews several studies highlighting disparities in outcomes, including higher rates of disease reclassification and adverse pathology in Blac...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, experts debate the disparities in prostate cancer outcomes among different racial groups, particularly focusing on African American men. They challenge previous findings, noting that several studies have failed to replicate significant differences in progression rates when access to care is equal...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Howard Wolinsky, a medical journalist and prostate cancer patient, shares his experience with active surveillance (AS) and presents findings from a survey of over 450 AS patients. He discusses the financial and emotional challenges faced by low-risk patients, including difficulties obtaining life...
|
- Details
- At the CAncer or Not Cancer: Evaluating and Reconsidering GG1 prostate cancer (CANCER-GG1?) Symposium, Leszek Izdebski discusses the complex decision-making process for prostate cancer patients considering active surveillance (AS). He emphasizes the importance of quality of life considerations, noting that different patients have varying priorities, such as maintaining the ability to participate i...
|
